mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cellular Signaling

Background:

• Mammalian target of rapamycin (mTOR) signaling is crucial for cellular functions and frequently dysregulated in pancreatic cancer.
• Current therapeutic strategies primarily target the mTORC1 complex, but clinical trials in pancreatic cancer have yielded disappointing results.
• This suggests a need to explore alternative mTOR signaling pathways, such as mTORC2, for effective treatment.

Purpose of the Study:

• To investigate the role of mTORC2 signaling in pancreatic tumorigenesis.
• To evaluate the efficacy of dual mTORC1/2 inhibition and combined PI3K inhibition in preclinical models of pancreatic cancer.

Main Methods:

• Genetic deletion of Rictor, an obligate mTORC2 subunit, to assess its impact on tumorigenesis.
• Treatment of tumor-bearing mice with a dual mTORC1/2 inhibitor.
• Combination therapy involving mTORC1/2 and PI3K inhibitors in late-stage pancreatic cancer models.

Main Results:

• Rictor deletion significantly delayed pancreatic tumor development, highlighting mTORC2's critical role.
• Unlike mTORC1 inhibitors, a dual mTORC1/2 inhibitor effectively suppressed tumorigenesis.
• Combined mTORC1/2 and PI3K inhibition markedly improved survival in mice with advanced pancreatic tumors.

Conclusions:

• mTORC2 signaling is a critical driver of pancreatic tumorigenesis.
• Dual inhibition of mTORC1 and mTORC2, or combination with PI3K inhibition, represents a promising therapeutic strategy for pancreatic cancer.
• Targeting the mTOR pathway warrants further investigation for pancreatic cancer treatment.